Kyowa Kirin Co., Ltd. · TSE:4151

Kyowa Kirin — Q3 2026 Earnings Presentation

47 slides from Kyowa Kirin's earnings presentation, November 2026

  1. Slide 1: Results Presentation Fiscal 2026 Third Quarter

    Results Presentation Fiscal 2026 Third Quarter

  2. Slide 2: Delivering Life-changing value to Patients

    Delivering Life-changing value to Patients Commitment to Life Luis Miguel Berlanas, Father of Candela, affected by XLH Commitment to Life We remain dedicated to our mission of delivering life-changing value to everyone battling illness, as we continue to push the boundaries of innovative drug discov

  3. Slide 3: Agenda

    Agenda 01 Q3 2026 Highlights Chairman Masashi Miyamoto 02 Financial Review President and Chief Executive Officer (CEO) Abdul Mullick 03 Commercial update Chief Medical Officer (CMO) Yoshifumi Torii 04 Business update Chief Financial Officer (CFO) Koji Igarashi 05 R&D update © Kyowa Kirin Co., Ltd. 2

  4. Slide 4: Executive Summary: Q3 2026 Highlights

    Executive Summary: Q3 2026 Highlights ◼ Dialogue with Stakeholders ◼ Q3 Financial Results ⚫ Revenue increased by 10% and Core operating profit by 47% year on year ⚫ Core operating profit progressing steadily against the revised full-year plan (75% progress) ⚫ Potential to exceed the full-year plan,

  5. Slide 5: Dialogue with Patients

    Dialogue with Patients Patient and family voices are at the heart of how we create and deliver value. XLH Day 2026 October 2-4, 2026 | Indianapolis, USA | Organizer: XLH Network Listening directly to patients' voices 1 CEO Abdul Mullick heard directly from patients about their XLH journeys and the d

  6. Slide 6: Dialogue with Investors / Shareholders

    Dialogue with Investors / Shareholders Tokyo Research Park Tour: Dialogue with Investors and Shareholders Event Overview Date and Time September 10, 2026 Composition Part 1: Presentation & Q&A / Part 2: Facility tour Venue Tokyo Research Park (TRP) History of our technologies (POTELLIGENT®/REGULGENT

  7. Slide 7: Incorporating Stakeholder Voices into Management Discussions

    Incorporating Stakeholder Voices into Management Discussions Continuing dialogue with key stakeholders and leveraging it in management discussions to shape our business strategy Patients ⚫ Hearing directly from patients at patient advocacy group events and at internal management meetings to which pa

  8. Slide 8: Financial Review

    Financial Review © Kyowa Kirin Co., Ltd. 7

  9. Slide 9: Summary of FY26 Q3 (YTD) Results

    Summary of FY26 Q3 (YTD) Results Q3 delivered revenue and profit growth, with greater confidence in achieving the full-year plan supported by favorable FX (Billion JPY / Rounded) FY2025 FY2026 FY2026 Change Progress Jan-Sep Jan-Sep Rev. Plans*3 Revenue 349.5 384.9 +35.5 520.0 74% [Overseas Ratio] [7

  10. Slide 10: YoY Analysis ~Revenue~ by Region

    YoY Analysis ~Revenue~ by Region Revenue Up on North America, Tech Income and FX, Despite Lapse of EMEA Prior-Year Brand Transfer Income ・Rocatinlimab upfront deferred revenue Temporary FY25 6.1 bn FY26 9.7 bn（+3.6 bn） (Billion JPY) factors ・EMEA established products brand transfer FY25 6.1 bn FY26

  11. Slide 11: YoY Analysis ~Revenue~ by Product

    YoY Analysis ~Revenue~ by Product Revenue up on double-digit Crysvita/Poteligeo growth and tech-licensing ・Rocatinlimab upfront deferred revenue Temporary FY25 6.1 bn FY26 9.7 bn (+3.6 bn) factors ・EMEA established products brand transfer (Billion JPY) FY25 6.1 bn FY26 - bn (-6.1 bn) FY25 Jan-Sep 34

  12. Slide 12: YoY Analysis ~Core Operating Profit~

    YoY Analysis ~Core Operating Profit*1~ Core operating profit up on global products, Tech-licensing income, and reduced rocatinlimab development costs (Billion JPY) FY25 Jan-Sep 66.1 Gross Profit Gross profit increased due to higher revenue. Gross Profit +12.5 The gross profit margin increased by 1 p

  13. Slide 13: YoY Analysis ~Profit~

    YoY Analysis ~Profit~ Profit growth driven by higher core operating profit despite impairment losses and clinical trial closing costs related to rocatinlimab (Billion JPY) FY25 Jan-Sep 32.6 Amortization of intangible assets Increased amortization of sales rights due to the launch of KOMZIFTI Core +3

  14. Slide 14: Commercial Update

    Commercial Update Coordinated Actions to Maximize Patient Access to Global Strategic Products © Kyowa Kirin Co., Ltd. 13

  15. Slide 15: Crysvita 2026 Key Actions & Q3 Topics

    Crysvita 2026 Key Actions & Q3 Topics 2026 KEY ACTIONS 2026 Q3 TOPICS ◼ NA: ◼ Global: YTD Sales rev. YoY, in Yen +17%, annual plan progress rate 73% Continue investments in people and operations to support patient identification, customer education, and the evolution of patient support services. ◼ N

  16. Slide 16: Poteligeo 2026 Key Actions & Q3 Topics

    Poteligeo 2026 Key Actions & Q3 Topics 2026 KEY ACTIONS 2026 Q3 TOPICS ◼ Global: Support the Poteligeo franchise in MF/SS through aligned global execution and ◼ Global: YTD Sales rev. YoY, in Yen +15%, annual plan progress rate 71% continued use of clinical and real-world evidence to reinforce long-

  17. Slide 17: KOMZIFTI 2026 Key Actions & Q3 Topics

    KOMZIFTI 2026 Key Actions & Q3 Topics KEY ACTIONS IN 2026 2026 Q3 TOPICS ◼ KOMZIFTI’s efficacy, safety profile, and ease of use support its positioning ◼ Commercial efforts continue to support the successful launch of KOMZIFTI as a competitive option in R/R NPM1-mutated AML, with the potential for ◼

  18. Slide 18: Business Update

    Business Update © Kyowa Kirin Co., Ltd. 17

  19. Slide 19: Agreement with the U.S. Government

    Agreement with the U.S. Government​ Voluntary agreement with the U.S. government to improve access and lower the cost of medicines for Americans Participation in the GENEROUS model Certain medicines offered to state Medicaid patients at a discount Balanced pricing for new products Applicable new pro

  20. Slide 20: Orchard updates: Advancing Our Gene & Cell Therapy Platform

    Orchard updates: Advancing Our Gene & Cell Therapy Platform Gene and Cell Therapy Portfolio Expansion Libmeldy®/LenmeldyTM OTL-203 (MPS-IH) Revenue Growth ⚫ Completed a meeting with the FDA in MLD3 September 2026 on clinical and Newborn Screening ⚫ Revenue +66% YoY (Jan–Sep CMC plans and BLA5 submis

  21. Slide 21: R&D Update

    R&D Update © Kyowa Kirin Co., Ltd. 20

  22. Slide 22: Development Pipeline: News Flow (1)

    Development Pipeline: News Flow (1) New information highlighted in orange As of Nov 2, 2026 Product Indication Event Status KOMET-017（P3） Ongoing AML (1L/Combination) KOMET-007（P1）Presentation at EHA Already marketed as June 2026 ziftomenib Congress and Journal Publication KOMZIFTITM KOMET-J001 (P2,

  23. Slide 23: Development Pipeline: News Flow (2)

    Development Pipeline: News Flow (2) New information highlighted in orange As of Nov 2, 2026 Product Indication Event Status KK4277 SLE, CLE P1 Completed KK2260 Advanced or metastatic solid tumors P1 Ongoing KK2269 Advanced or metastatic solid tumors P1 Ongoing KK2845 AML and other Hematologic Malign

  24. Slide 24: KHK4951 Phase 2 Summary of Test Results

    Source: Kyowa Kirin, “Topline Results of the KHK4951 Phase 2 study in nAMD patients” disclosed on September 8, 2026. KHK4951 Phase 2 Summary of Test Results Achieved the company's pre-defined product profile targets Results suggest the potential of an eye drop-centered maintenance treatment strategy

  25. Slide 25: Appendix

    Appendix  Financial Information  R&D  Other Updates © Kyowa Kirin Co., Ltd. 24

  26. Slide 26: Revenue of Major Items

    Revenue of Major Items (Units are billion JPY, rounded) FY2025 FY2026 FY2026 YoY Change Key Reason Progress Product Name, etc. Jan-Sep Jan-Sep Rev. Plans* 146.7 171.5 +24.8 (+17%) 235.4 73% Japan 9.7 11.1 +1.4 (+14%) 14.7 75% North Crysvita America 92.0 107.5 +15.5 (+17%) Market Penetration EMEA 42.

  27. Slide 27: Impact on Business Performance

    Source: Kyowa Kirin, “Discontinuation of Clinical Trials for Rocatinlimab,” disclosed on March 4, 2026. Impact on Business Performance • Short-term profit increase due to elimination of SG&A and R&D expenses related to rocatinlimab • Certain negative profit impact expected in the medium to long term

  28. Slide 28: Change in Core Performance Metrics from FY2026

    Source: Kyowa Kirin, “FY2025 Financial Results Briefing,” disclosed on Feb 9, 2026. (Updated 2026 Plans) Change in Core Performance Metrics from FY2026 Background Reviewing performance management post 2021-2025 Mid-term Business Plan, we change core performance metrics anticipating the impact of IFR

  29. Slide 29: Impacts arising from the adoption of IFRS 18

    [Ref.] Impacts arising from the adoption of IFRS 18 “Presentation and Disclosure in Financial Statements From the fiscal year ending December 2027, the presentation of our consolidated statement of profit or loss will be revised as outlined below. Ahead of this change, we have updated our performanc

  30. Slide 30: Capital Allocation Policy (2026–2028)

    Source: Kyowa Kirin, “Kyowa Kirin Equity Story” disclosed in June 2026. Capital Allocation Policy (2026–2028) While properly allocating the generated cash flow to investments for organic growth and to dividends, we will also allocate cash for future inorganic growth with discipline. Source Allocatio

  31. Slide 31: P/L Impact on EMEA established medicines portfolio

    P/L Impact on EMEA established medicines portfolio Before After 2024 2025 2026 Aug 2023 Aug 2023 unrealized 49% of the transfer value £ 66.4M(JPY13.1B) £38.5M (JPY7.7B) *Incl. price adj. diff. for 3 Tostran until Oct 3 brands 1 brand brands transferred last year Product sales IP transfer IP transfer

  32. Slide 32: FX Info

    FX Info Period Avg. FX Rate (yen) 2025 2026 2026 YoY Jan-Sep Jan-Sep Rev. Plans* USD 149 159 +10 ¥150 GBP 195 213 +18 ¥205 EUR 165 185 +20 ¥180 FY2026 YTD Q3 FX Impact (vs FY25, billion yen) Revenue Core OP USD +12.3 +6.3 GBP +0.5 -1.4 EUR +5.6 +3.1 FY2026 FX Sensitivity (vs FY26 Rev. Plans, billion

  33. Slide 33: Ziftomenib ~Kura Oncology Collaboration~

    Ziftomenib ~Kura Oncology Collaboration~ US Ex-US ◼ Kura leads Dev. Dev. ◼ Dev. costs 50/50 ◼ Kyowa Kirin leads Dev. ◼ Kura funds Dev. (~2028) Commercial. ◼ Kyowa Kirin sells & books sales ◼ Kura books sales ◼ 50/50 Profit Share Sales Royalties ◼ Kyowa Kirin pays double-digit % sales royalties Suppl

  34. Slide 34: Crysvita ~Ultragenyx Collaboration~

    Crysvita ~Ultragenyx Collaboration~ Economic Terms ◼ Kyowa Kirin books sales US･Canada ◼ 50/50 profit share for 5 years post-launch ◼ From Yr 6 (Apr 27, 2023), tiered sales royalties to Ultragenyx (mid-to-high 20s%) ◼ Kyowa Kirin books sales Europe ◼ Sales royalties to Ultragenyx (<10%) ◼ Ultragenyx

  35. Slide 35: Key Development Pipeline (1)

    Key Development Pipeline (1) As of Nov 2, 2026 Planned Development Number of Disease in development*1 approval year*2 status Market size*3 patients*4 AML ziftomenib TBD P3 (Global) ★★★★ 20K (NPM1-m or KMT2A-r, Newly Diagnosed) Achondroplasia TBD P3 (Japan) ★ 1 in 20K live births KK8398 infigratinib

  36. Slide 36: Key Development Pipeline (2)

    Key Development Pipeline (2) As of Nov 2, 2026 Disease in Development*1 Development Status Modality, Technology Used Systemic Lupus Erythematosus KK4277 P1 (Japan/Asia) completed Antibody, POTELLIGENT® Cutaneous Lupus Erythematosus P1 KK2260 Advanced/Metastatic Solid Tumors (JP: Ongoing, US: Prep) A

  37. Slide 37: Key Development Pipeline: Future Plans

    Orange: Ongoing Key Development Pipeline: Future Plans Gray: Pre-initiation or Completed As of Nov 2, 2026 Development Product Name Target Disease Phase 2026 2027 2028 ＋ ALL P1a1 (KMT2A-r) KOMET- 0012 P1a1 (non NPM1-m / non-KMT2A-r AML) KOMET- 0073 P1 ziftomenib KOMET- AML 0084 P11 KOMET- 0175 P3 KO

  38. Slide 38: Key Development Pipeline: Future Plans

    Key Development Pipeline: Future Plans Orange: Ongoing Gray: Pre-initiation or Completed As of Nov 2, 2026 Development Product Name Target Disease Phase 2026 2027 2028 ＋ nAMD P2 September 2026 Topline Data Announcement KHK4951 tivozanib eyedrop DME P2 SLE KK4277 P1 P1 study has been completed. Revie

  39. Slide 39: Ziftomenib: Assets in focus disease areas

    Creating Innovative Life-changing value Assets in focus disease areas Ziftomenib In development for relapsed/refractory and front-line AML with NPM1 mutation, KMT2A rearrangement, and FLT3 mutation Differentiated by deep and durable efficacy, combinability with other agents, safety, and a simple dos

  40. Slide 40: KHK4951: Assets in focus disease areas

    Creating Innovative Assets in focus disease areas Strategic Partnering Assets Life-changing value KHK4951 In development for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Non-invasive eye drop option for maintenance therapy after induction treatment in diseases

  41. Slide 41: KK2845: Assets in focus disease areas

    Creating Innovative Life-changing value Assets in focus disease areas KK2845 Kyowa Kirin’s first ADC in development for relapsed/refractory acute myeloid leukemia (AML) Targeting TIM-3 with the ADC to reach leukemic stem cells and blasts — aiming for a fundamental cure of the disease Galectin-9 (TIM

  42. Slide 42: Est. Patients

    Est. Patients Country/ Disease Region Incidence Prevalence1 Source PTCL Japan, US, EU4+UK 9,000 / year Clarivate - Decision Resources NK/T-Cell Lymphoma/ Global Data - Epidemiology Intelligence CTCL Japan, US, EU4+UK 80,000 Clarivate - Decision Resources NK/T-Cell Lymphoma - Epidemiology Intelligenc

  43. Slide 43: Abbreviations

    Abbreviations AG Authorized Generic ALL Acute Lymphoblastic Leukemia AML Acute Myeloid Leukemia BS Biosimilar CTCL Cutaneous T-cell Lymphoma DME Diabetic Macular Edema EMEA Europe, Middle East, & Africa JP Japan LCM Lifecycle Management MLD Metachromatic Leukodystrophy MPS-IH Mucopolysaccharidosis t

  44. Slide 44: Reference Information URL

    Reference Information URL Vision 2030 and Beyond: Our Growth Story Kyowa Kirin Equity Story Integrated Report 2025 (February 2026) (June 2026) (May 2026) Click here for the material→ LINK Click here for the material→ LINK Click here for the material→ LINK © Kyowa Kirin Co., Ltd. 43

  45. Slide 45: Upcoming IR Event: Roundtable with Independent Outside Directors

    Upcoming IR Event: Roundtable with Independent Outside Directors Our independent outside directors will engage directly with investors and analysts on Board discussions and the oversight of management Takashi Oyamada, MBA Yukiko Ito, Ph.D. Kohei Kan Independent Outside Director Independent Outside D

  46. Slide 46: Forward-looking statements disclaimer

    This document contains forward-looking statements regarding the outlook, targets, plans, and other future-related matters of the Company (including its consolidated subsidiaries in Japan and overseas). These statements are based on our reasonable judgments using current information and forecasts but

  47. Slide 47: Contact for Inquiries Regarding This Material

    ～Contact for Inquiries Regarding This Material～ Kyowa Kirin Co., Ltd. Finance Dep., IR Group +81-3-5205-7206 / [email protected]

Kyowa Kirin — Q3 2026 Earnings Presentation on 6ix